Show simple item record

dc.contributor.authorYarnold, JR
dc.contributor.authorBrunt, AM
dc.contributor.authorChatterjee, S
dc.contributor.authorSomaiah, N
dc.contributor.authorKirby, AM
dc.date.accessioned2022-05-10T11:56:48Z
dc.date.accessioned2022-05-10T11:58:39Z
dc.date.available2022-05-10T11:58:39Z
dc.date.issued2022-05-01
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2022, 34 (5), pp. 332 - 339
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5122
dc.identifier.eissn1433-2981
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2022.03.001
dc.identifier.doi10.1016/j.clon.2022.03.001
dc.description.abstractThere is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of hypofractionation in breast cancer derived from a series of clinical trials that began when 50 Gy in 25 fractions over 5 weeks was commonplace. These trials led first to 40 Gy in 15 fractions over 3 weeks and, subsequently, to 26 Gy in five fractions over 1 week being adopted as standards of care for many patients prescribed whole- or partial-breast radiotherapy after primary surgery.
dc.formatPrint-Electronic
dc.format.extent332 - 339
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE LONDON
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/5121
dc.relation.replacesinternal/5121
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectBreast
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectTreatment Outcome
dc.subjectRadiotherapy, Adjuvant
dc.subjectFemale
dc.subjectRadiation Dose Hypofractionation
dc.titleFrom 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy.
dc.typeJournal Article
dcterms.dateAccepted2022-03-01
rioxxterms.versionAM
rioxxterms.versionofrecord10.1016/j.clon.2022.03.001
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusAccepted
pubs.volume34
pubs.embargo.termsNot known
icr.researchteamBreast Cancer Radiotherapy
icr.researchteamTranslational Breast Radiobiology
dc.contributor.icrauthorYarnold, John
dc.contributor.icrauthorSomaiah, Navita


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record